A Randomized, Open Label, Multicenter, Comparative Phase II Trial of Ipilimumab After Isolated Limb Perfusion (ILP), in Patients With In-transit Metastases Melanoma Stage IIIB and IIIC
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2016
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Jun 2016 Status changed from recruiting to completed.
- 02 Jun 2015 Interim results (n=4) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 06 May 2014 New trial record